KLKe-Yan Loo

Ke-Yan Loo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ke-Yan Loo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Vengadesh Letchumanan

    Jeffrey Cheah School of Medicine and Health Sciences Novel Bacteria and Drug Discovery Research Group (NBDD) Microbiome and Bioresource Research Strength (MBRS) Monash University Malaysia Bandar Sunway Selangor Darul Ehsan 47500 Malaysia

    9 shared publications
  • Jodi Woan-Fei Law

    Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia

    8 shared publications
  • Loh Teng-Hern Tan

    Next-Generation Precision Medicine and Therapeutics Research Group (NMeT), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia

    8 shared publications
  • Learn-Han Lee

    Microbiome Research Group, Research Centre for Life Science and Healthcare, Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute (CBI), University of Nottingham Ningbo China, Ningbo 315000, China

    6 shared publications
  • Priyia Pusparajah

    Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Melbourne, VIC 3800, Australia

    6 shared publications
  • Kok-Gan Chan

    Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia

    5 shared publications

Latest Publications

  • Open Access

    Complete Whole-Genome Sequence of Streptomyces sp. MUM 178J, a Potential Anti-Vibrio Agent

    by Ke-Yan Loo, Loh Teng-Hern Tan, Kah-Ooi Chua, Priyia Pusparajah, Kok-Gan Chan, Learn-Han Lee, Jodi Woan-Fei Law, Vengadesh Letchumanan

    Streptomyces sp. is a group of filamentous, Gram-positive bacteria notoriously known for their capabilities in producing bioactive compounds that have been used as novel drugs and lead in drug development. The Streptomyces sp. MUM 178J was isolated from a mangrove forest in Malaysia. This isolate was found to harbor anti-Vibrio properties as its crude extract inhibited the growth of multidrug-resistant Vibrio parahaemolyticus. Therefore, the strain was subjected to whole genome sequencing to unearth its genomic potential. The genome of Streptomyces sp. MUM 178J consists of 6,699,249 bp with a G+C content of 71.3%. 66 tRNA genes and 18 rRNA genes were also predicted to be present within the genome. Further analysis with the bioinformatics tool, antiSMASH (antibiotics & Secondary Metabolite Analysis Shell), detected nine biosynthetic gene clusters displaying more than 70% similarity to known gene clusters, including one associated with melanin production. Melanin has demonstrated antagonistic activity against the growth of members of the Vibrio family, including V. parahaemolyticus. This indicates the potential correlation between the production of melanin and the anti-Vibrio properties of MUM 178J. The availability of the whole genome sequence of Streptomyces sp. MUM 178J allows for future in-depth investigation and potential exploitation of MUM 178J to harvest useful bioactive compounds.


  • Open Access

    Complete Whole Genome Sequence of Vibrio parahaemolyticus RP0132 Strain Isolated from Shrimp in Malaysia

    by Ke-Yan Loo, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Kah-Ooi Chua, Priyia Pusparajah, Learn-Han Lee, Vengadesh Letchumanan

    Vibrio parahaemolyticus is a Gram-negative, halophilic bacterium that is ubiquitous in marine environments. Its perilous co-existence with aquatic animals increases the risk of infections and diseases, especially those in aquaculture systems, thus resulting in reduced production and economic losses in the aquaculture industry. Moreover, V. parahaemolyticus can be easily transmitted to humans via consumption of contaminated seafood, resulting in gastroenteritis outbreaks. However, the rise in multidrug resistance within the species has challenged the efficacy of antimicrobial treatments against V. parahaemolyticus infections. Therefore, we report the genome sequence of V. parahaemolyticus RP0132 isolated from shrimp to gain insight into its antimicrobial resistance traits and potential resistance mechanisms. The findings will facilitate the development of effective anti-Vibrio agents to manage V. parahaemolyticus infections.


  • Open Access

    Detection of multidrug resistant Vibrio parahaemolyticus and anti-Vibrio Streptomyces sp. MUM 178J

    by Ke-Yan Loo, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Priyia Pusparajah, Learn-Han Lee, Vengadesh Letchumanan

    The growing global population has increased the demand for seafood, making the aquaculture industry a vital food source. However, climate change has negatively impacted the industry as natural inhabitants of aquatic environments such as Vibrio parahaemolyticus are thriving in the warming waters. These foodborne pathogens can cause disease in marine animals, resulting in lowered production rates and substantial economic losses. V. parahaemolyticus is transmitted from these marine animals in aquaculture to humans via raw or undercooked seafood, resulting in gastroenteritis outbreaks. In addition, the extensive use of antibiotics in aquaculture to treat infections within marine animals has led to the development of multidrug-resistant (MDR) V. parahaemolyticus, which threatens the effectiveness of antimicrobial treatments. Thus, it is vital to explore the alternatives of antibiotics in aquaculture to manage the spread of antibiotic resistance. This study aimed to investigate the prevalence of MDR V. parahaemolyticus to provide insight into the current antibiotic resistance patterns of this pathogen and to determine potential anti-Vibrio properties of Streptomyces MUM 178J which was previously isolated from the soils of a mangrove forest in Sarawak, Malaysia. Colony morphology and toxR-assay indicated that all samples tested positive for V. parahaemolyticus. Further identification with genomic analyses confirmed that 64% (64/100) of the isolates were V. parahaemolyticus. The multiple antibiotic resistance index (MAR) of the isolates ranged between 0.07 and 0.57, with 81% (52/64) of the isolates resistant to more than one antibiotic. The isolates were most resistant to ampicillin (98.4%), followed by ceftazidime (53.1%). In contrast, the isolates were highly susceptible to nalidixic acid (98.4%), tetracycline (93.8%), and sulfamethoxazole/trimethoprim (90.6%). They also demonstrated susceptibilities of 89.1% to levofloxacin, oxytetracycline, and gentamicin. Streptomyces sp. MUM 178J exhibited antagonistic effects on select V. parahaemolyticus strain, RP0132, with a minimum inhibitory concentration of 12.5 mg/mL and a minimum bactericidal concentration of 50 mg/mL.


  • Open Access

    The Burden of Vibrio sp. Infections – A Scoping Review

    by Ke-Yan Loo, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Priyia Pusparajah, Sunny Hei Wong, Kok-Gan Chan, Learn-Han Lee, Vengadesh Letchumanan

    Vibrios are a group of Gram-negative bacteria ubiquitous in our surrounding environments and responsible for various clinically significant human infections. The three species responsible for human illness are Vibrio cholerae, Vibrio parahaemolyticus, and Vibrio vulnificus. V. cholerae causes cholera which may result in severe dehydration and death without timely treatment, V. parahaemolyticus infection causes gastroenteritis while V. vulnificus infections typically manifest as wound or soft tissue infections with poor prognosis, including amputation or death. Available data on the epidemiology and clinical burden of Vibrio infections were compiled systematically following a literature review, and 149 relevant studies published between 2010 to 2022 were identified. Cholera represents the majority of Vibrio infections, affecting individuals of all ages and gender, while V. parahaemolyticus infections were found to affect mostly adult males. V. vulnificus infections were mostly reported in males over 50 years old with pre-existing co-morbidities. This review's findings may guide planning and implementing preventative measures in affected regions to prevent future Vibrio infections, disease transmission, and major outbreaks.


  • Open Access

    Vibrio parahaemolyticus: Exploring its Incidence in Malaysia and the Potential of Streptomyces sp. as an Anti-Vibrio Agent

    by Ke-Yan Loo, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Priyia Pusparajah, Sunny Hei Wong, Kok-Gan Chan, Learn-Han Lee, Vengadesh Letchumanan

    As the world recovers from the COVID-19 pandemic, concern remains for future potential outbreaks because of the persisting effects of climate change, including the proliferation of infectious diseases. The frequent isolation of Vibrio parahaemolyticus in the surrounding environment is of concern as it can cause infections in marine animals and transmitted to humans. V. parahaemolyticus is the leading cause of foodborne gastroenteritis worldwide. Malaysia is one of the top seafood consumers and this places us at a higher risk of exposure to V. parahaemolyticus infections. Over the years, this foodborne pathogen has been isolated from various sources in Malaysia, mainly from seafood such as shellfish, shrimps, and fish. To make matters worse, there has been an emergence of antibiotic-resistant V. parahaemolyticus worldwide, which is attributed to the uncontrolled use of antibiotics in aquaculture to prevent and treat vibriosis. Therefore, it is vital to utilize alternatives such as probiotics to control V. parahaemolyticus to prevent further propagation of antibiotic-resistant strains of the bacteria. A potential candidate for probiotics is Streptomyces sp., a class of filamentous, Gram-positive bacteria that produce a variety of bioactive compounds during their life cycle, which can be useful in drug discovery. The bioactive compounds produced by Streptomyces sp. have been proven to have microbiota-modulating and stimulatory effects on the host, enhancing immunity and providing protective effects against V. parahaemolyticus infections. With the application of Streptomyces sp. as probiotics in aquaculture, the efficacy of the available antibiotics can be preserved, and the further spread of antibiotic resistance in the environment can be reduced.


  • Open Access

    COVID-19: An Update on the Latest Therapeutic Agents

    by Ke-Yan Loo, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Kar-Wai Hong, Kok-Gan Chan, Vengadesh Letchumanan

    The COVID-19 pandemic has plagued the world for over three years since discovering the causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of livelihoods of millions across the globe. This public health emergency prompted the rapid development of vaccines and treatments to fight against viral infection. Vaccines against the viral infection started rolling out in late 2020, and the distribution of the vaccines worldwide managed to reduce the symptoms of COVID-19 and prevent outbreaks in local communities. However, COVID-19 infections are still prevalent, with patients suffering from severe symptoms which require oxygen support or mechanical ventilation. Thus, therapeutic agents for COVID-19 play a significant role in reducing the risk of disease progression into severe disease and improving hospitalized patients' clinical outcomes. Existing drugs such as remdesivir, molnupiravir, baricitinib, anakinra, and tocilizumab have been repurposed to treat COVID-19 earlier during the pandemic to meet the urgent demand for treatment. There are also novel antiviral and immunomodulating treatments (nirmatrelvir plus ritonavir, ensitrelvir, regdanvimab, sotrovimab, and vilobelimab) that were developed during the pandemic to fight against COVID-19 infections. These therapeutic agents have been reported to be effective and safe for use to treat COVID-19 infections of different severity. Nevertheless, continuous surveillance is imperative in ensuring that these treatment methods maintain efficacy and safety profiles in treating COVID-19 caused by different variants of the virus.


  • Open Access

    Exploring the impact of Helicobacter pylori and potential gut microbiome modulation

    by Isaac Jingkhai Ong, Ke-Yan Loo, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Vengadesh Letchumanan

    Helicobacter pylori is a highly prevalent bacteria that can harm humans due to its major involvement in developing gastrointestinal diseases, particularly gastric cancer. Therefore, eradicating H. pylori is one of the most important strategies for preventing gastric cancer. Antibiotic treatment has always been the gold standard treatment for H. pylori infection. However, the decreasing efficacy of antibiotic therapy due to the rising antibiotic resistance and high incidence of dysbiosis-related adverse effects resulted in eradication failure. To enhance the effectiveness of antibiotic therapy, strategies that modulate the gut microbiome were proposed to play a positive role. Generally, the integration of probiotics or symbiotic into antibiotic therapy was shown to enhance the eradication rate and reduce the incidence of adverse effects. This review aims to discuss the role and effect of H. pylori in gastric carcinogenesis and gut microbiome modulation in eradicating H. pylori infection.


  • Open Access

    COVID-19: Understanding the New Variants of Concern

    by Ke-Yan Loo, Vengadesh Letchumanan

    The novel coronavirus, SARS-CoV-2, part of the Coronaviridae family, was discovered in December 2019 in China. World Health Organization named it COVID-19 and by March 2020, it had spread worldwide, causing a global pandemic. Despite continuous efforts to prevent the spread of the virus, the virus seemed always to be a step ahead of humankind as it rapidly evolved to produce new variants. These variants have higher transmissibility than the original virus and were responsible for new waves of infections. The first variant was Alpha, followed by the discovery of Beta, Gamma, Delta, and Omicron, being the latest variant of concern. Although vaccines were distributed worldwide to reduce the severity of the disease when infected with SARS-CoV-2, the emergence of new variants raised doubts about the efficacy of the available vaccines. Studies showed a decrease in neutralizing antibodies during infection with XBB and BQ subvariants compared to infections caused by other variants. Fortunately, early evidence shows that the mRNA vaccines are still effective against the current circulating Omicron sublineages of the coronavirus. Nevertheless, continuous genomic surveillance of the coronavirus is still important to detect any new variants of concern to assess their potential to threaten public health. The efficacy of vaccines and treatment options available against the latest circulating variant of SARS-CoV-2 should also be periodically evaluated. This ensures that the treatment and vaccines used are safe and effective against the virus to protect the public from another health crisis.


  • Open Access

    COVID-19: Insights into Potential Vaccines

    by Ke-Yan Loo, Vengadesh Letchumanan, Hooi-Leng Ser, Siew Li Teoh, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Nurul-Syakima Ab Mutalib, Kok-Gan Chan, Learn-Han Lee

    People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.


  • Open Access

    Omicron: The rising fear for another wave in Malaysia

    by Lydia Ngiik-Shiew Law, Ke-Yan Loo, Joanna Xuan Hui Goh, Priyia Pusparajah

    The past two years have been a turmoil for the world and people due to the COVID-19 pandemic. It was the first time in history that the whole world was on a standstill after many countries-imposed movement control orders and restrictions. Many innocent lives were lost, and the spread of infection is still ongoing. Pharmaceutical companies raced against the time to develop vaccines, believing that it would be sufficient to control COVID-19. Nevertheless, the recent emergence of the SARS-CoV-2 variant as Omicron has become a global concern. This new variant of concern (VOC) spreads faster than other VOC strains and poses a high risk, mounting fears of new waves of infections in many countries, including Malaysia. This review discussed characteristics of Omicron, the emergence of Omicron cases in Malaysia, and preventive measures to control the spread of COVID-19.